A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
11/2002
11/13/2002	EP1255833A2 Polypeptides and nucleic acids encoding same
11/13/2002	EP1255821A2 Protein c derivatives
11/13/2002	EP1255760A1 Clavams as protease inhibitors
11/13/2002	EP1255757A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
11/13/2002	EP1255751A2 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors
11/13/2002	EP1255750A1 INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
11/13/2002	EP1255748A1 Beta-alanine derivatives and their use as receptor antagonists
11/13/2002	EP1255744A1 Substituted phenylamidines medicaments containing said compounds and method for production thereof
11/13/2002	EP1255743A1 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
11/13/2002	EP1255741A2 2- 1H]-QUINOLONE AND 2- 1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
11/13/2002	EP1255557A1 Stable, nasally, orally or sublingually applicable pharmaceutical preparation
11/13/2002	EP1255545A2 L-arginine in combination with other compounds for treating cardiovascular diseases
11/13/2002	EP1107968B1 Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one
11/13/2002	EP1007078A4 Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
11/13/2002	EP0949921B1 Thrombin inhibitors
11/13/2002	EP0699074B1 Thrombin inhibitors
11/13/2002	CN1379814A Embryonic or stem-like cell lines produced by cross species nuclear transpcantation and methods for enhancing mebryonic development by genetic alteration of donor cells or by tissue culture conditions
11/13/2002	CN1379772A Substituted indoles for modulating NFKB activity
11/13/2002	CN1379761A Condensed indoline derivatives and their use as 5HT, in particular 5HT2C receptor ligands
11/13/2002	CN1379755A Substituted 2-dialkylamino alkylbiphenyl derivatives
11/13/2002	CN1379676A Blood plasma replacement composition
11/13/2002	CN1379669A Valdecoxib compositions
11/13/2002	CN1378837A Application of danshinolic acid compounds in preparing medicines
11/12/2002	US6479534 Indoline derivatives and method of treating obesity
11/12/2002	US6479524 To prolong the thrombin time
11/12/2002	US6479492 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/12/2002	US6479490 Treatment of diseases characterized by excess th2 cytokines and/ or an excess ige production.
11/12/2002	US6479485 Benzamidine derivatives and their use as anti-coagulants
11/12/2002	US6479261 Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells
11/12/2002	US6479250 Eck receptor ligands
11/12/2002	US6479245 Monoclonal antibody which is specific for activated coagulation factor VII, and its use
11/12/2002	US6479080 Plant extract
11/12/2002	US6479078 Substantially crystalline form of melagatran
11/12/2002	US6478765 Apparatus for removing thrombosis
11/12/2002	CA2009533C Novel cyclosporin galenic forms
11/11/2002	CA2385692A1 Thiazole derivatives
11/09/2002	CA2385412A1 Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
11/07/2002	WO2002088664A2 Control of compactability through crystallization
11/07/2002	WO2002088366A1 Von willebrand factor (vwf)-cleaving enzyme
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088186A1 Anti-cd40 monoclonal antibody
11/07/2002	WO2002088156A1 Lipid a 1-carboxylic acid derivative
11/07/2002	WO2002088118A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002	WO2002088097A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	WO2002088095A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	WO2002088094A1 2-iminoimidazole derivatives (1)
11/07/2002	WO2002088092A1 2-iminoimidazole derivative (2)
11/07/2002	WO2002088084A1 Heterocyclic compound derivatives and medicines
11/07/2002	WO2002087626A1 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same
11/07/2002	WO2002087605A2 Modified fvii in treatment of ards
11/07/2002	WO2002087597A1 Oral delivery of macromolecules
11/07/2002	WO2002087593A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
11/07/2002	WO2002087560A1 Carboxylic acid such as citric acid for desinfecting or enhacing the production of blood products such as plasma, cryoprecipitate or/and platelet
11/07/2002	WO2002087548A1 A pharmaceutical tablet having a high api content
11/07/2002	WO2002087508A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	WO2002087506A2 Method and apparatus for computer modeling diabetes
11/07/2002	WO2002087496A2 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
11/07/2002	WO2002067857A3 Modified annexin proteins and methods for preventing thrombosis
11/07/2002	WO2002064546A3 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/07/2002	WO2002009768A3 Therapeutic polyesters and polyamides
11/07/2002	WO2001085687A1 Substituted indoles as parp inhibitors
11/07/2002	WO2001027079A9 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
11/07/2002	WO2001026676A9 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
11/07/2002	WO2000064420A3 Compositions and methods for treating amyloidosis using sulphonate derivatives
11/07/2002	US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition
11/07/2002	US20020166130 Expression of active human factor IX in mammary tissue of transgenic animals
11/07/2002	US20020165412 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
11/07/2002	US20020165400 Antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex; thrombolytic agents
11/07/2002	US20020165399 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
11/07/2002	US20020165386 C-junction-n-terminal kinase (JNK); microbiocides; treating neurodegenerative diseases
11/07/2002	US20020165377 ADAM polynucleotides, polypeptides, and antibodies
11/07/2002	US20020165374 Secreted protein HFEAF41
11/07/2002	US20020165282 PPAR agonists
11/07/2002	US20020165268 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
11/07/2002	US20020165262 Methods and products relating to 16-HETE analogs
11/07/2002	US20020165247 Use of morphine derivatives as medicaments for the treatment of neuropathic problems
11/07/2002	US20020165235 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists
11/07/2002	US20020165179 Multifunctional nanodevice platform
11/07/2002	US20020165177 Modified factor VIII cDNA
11/07/2002	US20020165166 Treating thrombosis by administering a CD154 inhibitor, such as a metalloproteinase inhibitor
11/07/2002	US20020165150 Amino acid sequence from certain regions of tissue growth factor-beta super family serine-threonine kinase receptors
11/07/2002	US20020164768 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of thrombosis and vascular system disorders
11/07/2002	US20020164711 Megakaryocyte differentiation factor
11/07/2002	US20020164383 Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof
11/07/2002	US20020164377 Mixture of retinoic acid and paclitaxel; polymeric carrier
11/07/2002	US20020164355 Test to detect antibodies; calibration
11/07/2002	US20020164329 Adsorption and removal of endotoxin from physiological fluids using cationic helix peptides
11/07/2002	CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	CA2446064A1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	CA2445811A1 Modified fvii in treatment of ards
11/07/2002	CA2445702A1 Control of compactability through crystallization
11/07/2002	CA2445629A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002	CA2445598A1 Method and apparatus for computer modeling diabetes
11/07/2002	CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	CA2445349A1 Anti-cd40 monoclonal antibody
11/07/2002	CA2445338A1 G-protein coupled receptors
11/07/2002	CA2445290A1 A pharmaceutical tablet having a high api content
11/07/2002	CA2438223A1 Carboxylic acid such as citric acid for desinfecting or enhacing the production of blood products such as plasma, cryoprecipitate or/and platelet
11/07/2002	CA2408369A1 Substituted indoles as parp inhibitors
11/06/2002	EP1254944A1 Dry compositions containing hydrophobic amino acid

1 ... 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 ... 671